Peter Kabos

4.2k total citations
100 papers, 2.5k citations indexed

About

Peter Kabos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Peter Kabos has authored 100 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Peter Kabos's work include Advanced Breast Cancer Therapies (39 papers), HER2/EGFR in Cancer Research (25 papers) and Cancer Treatment and Pharmacology (25 papers). Peter Kabos is often cited by papers focused on Advanced Breast Cancer Therapies (39 papers), HER2/EGFR in Cancer Research (25 papers) and Cancer Treatment and Pharmacology (25 papers). Peter Kabos collaborates with scholars based in United States, Belgium and Spain. Peter Kabos's co-authors include Carol A. Sartorius, Anthony Elias, Austin E. Gillen, Jessica Finlay-Schultz, J. Chuck Harrell, Diana M. Cittelly, Kathryn B. Horwitz, Manoj M. Pillai, Wendy W. Dye and Virginia F. Borges and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Peter Kabos

96 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Kabos United States	31	1.5k	1.0k	828	740	393	100	2.5k
Jeremy Hoog United States	18	1.6k 1.1×	1.1k 1.1×	993 1.2×	863 1.2×	352 0.9×	35	2.7k
Seth A. Wander United States	25	1.5k 1.0×	1.3k 1.3×	1.1k 1.4×	791 1.1×	219 0.6×	108	2.9k
Mónica V. Estrada United States	16	1.4k 0.9×	1.3k 1.3×	677 0.8×	925 1.3×	117 0.3×	25	2.5k
Bárbara Adamo Spain	25	1.8k 1.2×	1.7k 1.7×	1.0k 1.2×	1.4k 1.9×	298 0.8×	99	3.7k
Diana Mandelker United States	23	867 0.6×	1.3k 1.3×	482 0.6×	718 1.0×	311 0.8×	94	2.5k
Ricardo H. Álvarez United States	28	1.7k 1.2×	824 0.8×	558 0.7×	1.1k 1.4×	118 0.3×	75	2.7k
Patricia Galván Spain	20	1.4k 0.9×	947 0.9×	671 0.8×	997 1.3×	180 0.5×	69	2.4k
Viive M. Howell Australia	26	672 0.5×	852 0.8×	418 0.5×	568 0.8×	306 0.8×	74	2.2k
Alessia Ciarrocchi Italy	33	1.2k 0.8×	2.4k 2.4×	639 0.8×	1.0k 1.4×	211 0.5×	115	4.0k
Sarah Halford United Kingdom	27	1.4k 1.0×	1.1k 1.1×	253 0.3×	735 1.0×	365 0.9×	51	2.5k

Countries citing papers authored by Peter Kabos

Since Specialization

Citations

This map shows the geographic impact of Peter Kabos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kabos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kabos more than expected).

Fields of papers citing papers by Peter Kabos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kabos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kabos. The network helps show where Peter Kabos may publish in the future.

Co-authorship network of co-authors of Peter Kabos

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kabos. A scholar is included among the top collaborators of Peter Kabos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kabos. Peter Kabos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Shagisultanova, Elena, William J. Gradishar, Pavani Chalasani, et al.. (2023). Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Clinical Cancer Research. 29(24). 5021–5030. 8 indexed citations

Ormond, D. Ryan, et al.. (2023). Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis. Neuro-Oncology. 25(10). 1802–1814. 5 indexed citations

Fisher, Christine M., et al.. (2023). Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience. Journal of Neuro-Oncology. 163(1). 115–121. 4 indexed citations

McGinn, Olivia, et al.. (2022). Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Molecular Cancer Research. 20(9). 1443–1455. 11 indexed citations

Sartorius, Carol A., et al.. (2022). Transcription factor–nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Science Advances. 8(34). eabm4358–eabm4358. 13 indexed citations

Bardia, Aditya, Virginia Kaklamani, Sharon Wilks, et al.. (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology. 39(12). 1360–1370. 67 indexed citations

Brechbuhl, Heather M., Mengyu Xie, Kiran Paul, et al.. (2021). Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor‐positive breast cancer. Molecular Carcinogenesis. 61(3). 359–371. 5 indexed citations

Marquez-Ortíz, Ricaurte Alejandro, Vesna Tešić, James C. Costello, et al.. (2021). IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clinical Cancer Research. 27(22). 6209–6221. 22 indexed citations

10.

Weiss, Jennifer, et al.. (2021). Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Frontiers in Oncology. 11. 640690–640690. 9 indexed citations

11.

Tolaney, Sara M., Solmaz Sahebjam, Émilie Le Rhun, et al.. (2020). A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 26(20). 5310–5319. 144 indexed citations

12.

Weiss, Jennifer, Dexiang Gao, Christine M. Fisher, et al.. (2020). Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Medicine. 9(23). 8801–8808. 1 indexed citations

13.

Kumthekar, Priya, Shou‐Ching Tang, Andrew Brenner, et al.. (2020). ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research. 26(12). 2789–2799. 178 indexed citations

14.

Cittelly, Diana M., Tyler P. Robin, Julie A. Carlson, et al.. (2019). Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clinical Cancer Research. 25(13). 3946–3953. 49 indexed citations

15.

Riemondy, Kent, Monica Ransom, Christopher P Alderman, et al.. (2018). Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Research. 47(4). e20–e20. 14 indexed citations

16.

Stokes, William A., Matthew W. Jackson, Nicole Kounalakis, et al.. (2017). Disparities and Patterns of Care in Boost Utilization for Early-Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 99(2). E416–E416. 1 indexed citations

17.

Mazières, Julien, Sara M. Tolaney, Luis Paz‐Ares, et al.. (2017). P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1076–S1077. 2 indexed citations

18.

Brechbuhl, Heather M., Jessica Finlay-Schultz, Tomomi M. Yamamoto, et al.. (2016). Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clinical Cancer Research. 23(7). 1710–1721. 164 indexed citations

19.

Kumthekar, Priya, Shou‐Ching Tang, Andrew Brenner, et al.. (2016). OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer. Neuro-Oncology. 18(suppl_4). iv16–iv16. 7 indexed citations

20.

Tentler, John J., Aik Choon Tan, Todd M. Pitts, et al.. (2015). p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14(5). 1117–1129. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact